AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01831986 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Caps
Study NCT00501332 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Maxy-G34
Description: Maxy-G34 will be administered by subcutaneous injection during each of 6 TAC chemotherapy cycles.
Study NCT02704481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo mifepristone
Description: Matching placebo pill of 200mg mifepristone
Study NCT02704481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo misoprostol
Description: Matching placebo pills of 800mcg misoprostol
Study NCT02330965 — intervention group
Intervention type: PROCEDURE
Intervention: CSF collection by lumbar puncture (Optional)
Description: For participants who volunteer to donate CSF samples: up to 25 mLs (\<2 tablespoons): prior to study medication initiation, and at month 24 post treatment initiation.
Study NCT03890952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Treatment with the combination of Nivolumab and bevacizumab every 2 weeks
Study NCT03890952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Treatment with the combination of Nivolumab and bevacizumab every 2 weeks
Study NCT01729871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Description: rivaroxaban 20 mg orally, once-daily, administered preferably with the evening meal
Study NCT01729871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: uninterrupted vitamin K antagonist (VKA)
Description: dose-adjusted vitamin K antagonist (VKA) to achieve a recommended International Normalized Ratio (INR) of 2.0 to 3.0
Study NCT01838551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoketoconazole
Description: Levoketoconazole is the 2S,4R- enantiomer derived from racemic ketoconazole
Study NCT00508690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefmetazole
Description: Intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
Study NCT00508690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: kanamycin/metronidazole
Description: 2 doses of oral kanamycin(1g)/ metronidazole(750mg) administration on the day before surgery with intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
Study NCT02064751 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT with MultiPoint Pacing
Study NCT02064751 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodynamic measurements for CRT device programming
Study NCT03530280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin (lyrica)
Description: preoperative pregabalin and the postoperative sham block will perform.
Study NCT03530280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: The preoperative placebo oral tablet and the postoperative sham block will perform.
Study NCT03530280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adductor canal block including bupivacaine
Description: The preoperative placebo oral tablet and adductor channel block including 10 mL of 0.25% bupivacaine with 5 μg/mL epinephrine
Study NCT01585181 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PXVX0200
Description: Single dose; liquid suspension after reconstitution with buffer; 2x108 to 2x109 CFU in a liquid suspension
Study NCT01585181 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Approx 2 grams of lactose reconstituted in water
Study NCT02093923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DX-2930
Description: Participants will receive SC injection of DX-2930 (a recombinant, Chinese hamster ovary \[CHO\] cell expressed, fully human immunoglobulin IgG1, kappa light chain, monoclonal antibody) once and followed by the second dose after 2 week into the upper arm.
Study NCT02770664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02770664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC28-0126 Dose A
Description: LC28-0126 Dose A
Study NCT02093923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo subcutaneously.
Study NCT05908617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Discharge
Description: Patient will watch a video discharge instructions in addition to the standard paper instructions. They will also take the pre and post test as the control group
Study NCT05352438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy Group
Description: Patient education directed at parafunctional behaviors was given, and an exercise program was taught, with all the patients instructed to perform these exercises at home. The home exercise program included diaphragmatic breathing exercises, chin-tuck exercises, mandibular resistance exercises, and neck muscle stretching exercises. The patients were instructed to perform the exercises as 3 sets of 10 repetitions per day.~In addition to the patient education and home exercises, the Manual Therapy group received a manual therapy program applied as 2 sessions of 45 mins each week for 4 weeks (total 8 sessions) by an investigator. Soft tissue and joint mobilizations were applied to the TMJ and surrounding structures and to cervical segments, trigger point treatment was applied to trigger points, and myofascial loosening was performed. Patients were instructed to perform the exercises learned in the home exercise program in 3 sets of 10 repetitions every day.
Study NCT02770664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC28-0126 Dose B
Description: LC28-0126 Dose B
Study NCT02770664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC28-0126 Dose C
Description: LC28-0126 Dose C
Study NCT05352438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Splint Therapy Group
Description: Patient education directed at parafunctional behaviors was given, and an exercise program was taught, with all the patients instructed to perform these exercises at home. The home exercise program included diaphragmatic breathing exercises, chin-tuck exercises, mandibular resistance exercises, and neck muscle stretching exercises. The patients were instructed to perform the exercises as 3 sets of 10 repetitions per day.~In addition to the patient education and home exercises, the Splint Therapy group was given a static occlusal splint, and adjustments were made as necessary. All the patients in this group were instructed to use the splint when sleeping for a period of one month.
Study NCT04245293 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ainara
Description: Each administration kit (subject kit) for patients of Ainara® will contain a box with 1 tube with 30 g gel, 1 cannula and 1 plunger. The gel quantity is enough for one subject over the course of the study (1 g at each administration).
Study NCT04245293 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HyaloGin
Description: Active Comparator: HyaloGin Each administration kit (subject kit) for patients allocated to HyaloGyn® group will contain a box with: 1 tube with 30g gel and 10 single-use applicators consisting of a piston and one opaque plastic plunger.~The gel quantity is enough for one subject (3g application every three days over the course of the study).
Study NCT03084458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: The Fitbit device will allow experimental group participant access to their daily step count.
Study NCT04459832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stretch hamstring
Description: Stretching of the hamstring muscles was performed by the primary researcher. A straight-leg-raising technique was used for this stretch because we believe that it is commonly used in the clinical setting for elderly people. All subjects were supine lying as flat as possible
Study NCT00526435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk with Ease - Group
Description: Participate in 6-week, 1 hour per week group assisted classes (with instructor).
Study NCT00526435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk with Ease - Self
Description: SUbject will receive the WWE workbook and follow it without group/instructor assistance.
Study NCT04459832 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: stretch hamstring
Description: Stretching of the hamstring muscles was performed by the primary researcher. A straight-leg-raising technique was used for this stretch because we believe that it is commonly used in the clinical setting for elderly people. All subjects were supine lying as flat as possible
Study NCT03357822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon
Description: 180ug Pegylated interferon is injected subcutaneously once a week
Study NCT03357822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: 0.5mg entecavir is orally taken every day
Study NCT03357822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: 0.5mg entecavir is orally taken every day
Study NCT00379509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Patients will be assigned in cohorts of 3. Dose levels of GW572106 will include 500mg, 1000mg,1500 mg (additional levels at 750 mg and 1250 mg will be added if needed). Lapatinib is an oral drug. It is taken every day.
Study NCT00379509 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: TdT-mediated dUTP nick end labeling assay
Description: Genetic analysis of tumor tissue
Study NCT00379509 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Genetic analysis of tumor tissue.
Study NCT00379509 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Description: Genetic analysis of tumor tissue.
Study NCT00379509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Laboratory analysis of tumor tissue.
Study NCT00379509 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Serial biopsies by skin punch or core biopsy or fine needle aspiration.
Study NCT00379509 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiotherapy will be delivered at standard dose and fractionation. For patients who have not received previous locoregional radiotherapy, 50-56 Gy will be delivered to the regional lymph nodes and/or chest wall at a dose of 2 Gy per fraction, 5 days per week followed by a boost to the sites of gross involvement to a total dose of 60-70 Gy over a course of 6-7 weeks. For patients who have received adjuvant radiotherapy, a dose of 35-45 Gy will be delivered to sites of chest wall involvement at a dose of 1.8 Gy per fraction over 4-5 weeks. In either de novo or reirradiated settings, the total dose to the brachial plexus will not exceed 60 Gy.
Study NCT01396694 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire
Study NCT03895229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG Oral Tablet [Jardiance]
Description: Empagliflozin is a sodium-glucose co-transporter 2 inhibitor approved for treatment of type 2 diabetes mellitus
Study NCT01557062 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Polysomnography
Description: The Embla® S7000 was used to record full-night at the Sleep Institute (São Paulo, Brazil). The sensors were attached to the patient in a non-invasive manner using tape or rubber bands. The physiological variables were monitored simultaneously and continuously: 4 channels of EEG, 2 of EOG, 4 of EMG and 1 channel of ECG. Airflow detection was made through 2 channels using a pair of thermal sensors and nasal pressure. Respiratory effort of the chest and abdomen, were measured by respiratory inductance plethysmography. Oxygen saturation, were measured with a pulse oximeter. Sleep stages were visually scored in all the PSG according to standardized criteria for the investigation of sleep macrostructure.
Study NCT01557062 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Teperature measure
Description: Core body temperature was assessed using a thermistor pill (sensor), which is an electronic device 2.23 cm in length and 1.06 cm in diameter that records body temperature and transmits it to a receptor located at the patient's waist called the Core Body Temperature Monitoring System (CorTempTM), that is powered by a silver oxide battery. The components of the sensor are encapsulated in epoxy resin and coated with silicone (HQ Inc., Florida, USA). To ensure that the sensor would be in the intestines and not the stomach, the pill was ingested at least 2 hours (h) before beginning temperature recording. The CBT was recorded every 30 minutes (min) between 10:00pm and 7:00am. The time of pill elimination is variable between individuals and may be as long as 48h.
Study NCT01557062 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fibromyalgia Impact questionary
Description: The FIQ is an instrument used to assess the quality of life specifically for patients with FM. This questionnaire consists of 19 questions related to functional capacity, employment status, general well being, psychological disorders and physical symptoms. The higher the score is, the greater is the impact of FM in the individual's quality of life. This questionnaire was validated for Brazilian's population in 2006.
Study NCT03201263 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sigh
Description: Application of cyclic pressure control breath delivered at 30 cmH2O for 3 seconds once per minute in patients undergoing pressure support ventilation
Study NCT03201263 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care
Study NCT04396444 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Aromastick
Description: Vascular surgery patients will be randomized to either the intervention group and receive a lavender infused aromastick to use as an adjunct to their inpatient pain management plan, or to the control group, given a blank aromastick. Subjects will be blinded to their group.
Study NCT04396444 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Aromastick
Description: Vascular surgery patients will be randomized to either the intervention group and receive a lavender infused aromastick to use as an adjunct to their inpatient pain management plan, or to the control group, given a blank aromastick. Subjects will be blinded to their group.
Study NCT01229371 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inflexal V influenza vaccine (CSL HA Antigen) 2010
Description: Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011, with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
Study NCT01229371 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inflexal V influenza vaccine (AdImmune HA antigen) 2010/2011
Description: Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
Study NCT03225742 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: to measure the residual volume after catheterization
Description: after first micturition to measure the residual volume in bladder
Study NCT00826345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture / Moxibustion
Description: Acupuncture/Moxibustion points will be administered per point prescription.~- Active
Study NCT00826345 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture/Moxibustion
Description: Sham/Placebo Acupuncture/Moxibustion - Not active
Study NCT00568711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: a 5-day course of 100 mg bid doses of doxycycline
Study NCT00568711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rifampin
Description: a 5-day course of daily 600-mg doses of rifampin
Study NCT06163417 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic
Description: laparoscopic
Study NCT02715232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: 100mg testosterone undecanoat every 8-12 weeks, or alternatively 50mg testosterone transdermally, or 50mg testosterone creme
Study NCT02715232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lynestrenol
Description: 2-3 tablets/day, if menstruation still occurs
Study NCT02715232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproterone Acetate
Description: 25mg daily
Study NCT02715232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: 75 microgram transdermal therapeutic system twice a week, or p.o. estradiol 2x2mg/day, or estradiol gel 1,5-3mg
Study NCT04584008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.
Description: According to the treatment dose approved by NMPA/FDA, evaluation will be conducted every 2 cycles until tumor progression or adverse events cannot be tolerated.
Study NCT04584008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Other Therapy
Description: Patients will receive other treatments, including cytotoxic drugs, antiangiogenic drugs, best supportive care, clinical trials of unmatched new drugs, etc..
Study NCT00432965 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Moist Wound Therapy
Description: Moist Wound Therapy (Standard of Care)
Study NCT00432965 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VAC Therapy
Description: VAC Therapy
Study NCT03478488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN035 plus Gemcitabine & oxaliplatin
Description: KN035 a programmed death ligand immune check inhibitor Per Investigator decision
Study NCT03478488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine & oxaliplatin
Description: The standard of care for the patients with unresectable/metastatic biliary tract cancer
Study NCT03357822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate
Description: 300mg tenofovir is orally taken every day
Study NCT03357822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300mg tenofovir is orally taken every day
Study NCT01996345 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical Pessary Placement
Description: For the patients assigned to receive a cervical pessary, they will be evaluated and fitted for a pessary by the physician within 3-4 days unless exclusion criteria develop. After it is placed she will be evaluated for comfort. She will be asked to leave it in at all times but informed that removal and withdrawal from the study is always her option.
Study NCT03493308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education
Description: PNE will be conducted in line with international guidelines and will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.
Study NCT02715232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin acetate
Description: 4,12mg every 4-6 weeks (powder for suspension for injection s.c. or i.m.
Study NCT03493308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise will be provided in different formats including general exercise, strengthening, dance.
Study NCT00540449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC278
Description: 25 mg tablet once daily for 96 weeks
Study NCT00540449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: 600mg once daily for 96 weeks
Study NCT03524677 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Liquid Biopsy
Description: K-RAS, CDKN2A, SMAD4 and TP53 mutation on circulating cfDNA
Study NCT04000672 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D printed patient specific metal jigs (PSI jig)
Description: PSI jig is created based on the pre-operative CT image. Standard medial open wedge osteotomy described previously is performed. Incision is made in the midway between posteromedial border of the tibia and medial aspect of the tibial tuberosity. Sartorius fascia is cut and retracted medially to expose the medial collateral ligament (MCL). Then the PSI jig is positioned onto the tibia. Due to the jig patient specific design (individually based on each patient's CT image), it can fit closely to the proximal tibia. The slot opening on the PSI jig corresponds to 4 cm below the medial joint line and the slot design allow the sawblade cut direction toward the safe zone of the lateral cortex under fluoroscopy. The PSI Jig is removed after the bone cut completed and would not retain in patient's body.